denosumab
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Jubbonti | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
Ospomyv | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
Prolia | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
Stoboclo | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||
Conexxence | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL | ||||
Xgeva | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL |
Prolia medication guide
Prolia, Xgeva, and all denosumab (Prolia) biosimilars approved by the Committee are restricted to the hospital outpatient setting.
Ospomyv, Stoboclo, Conexxence, and Jubbonti are biosimilars to Prolia. The denosumab (Prolia) biosimilars approved by the Committee are classified as therapeutically equivalent and interchangeable to Prolia and other denosumab biosimilars for the FDA approved indications and literature supported off-label uses. The most cost-effective agent may be used in a given patient, situation, or time period.
Inpatient consideration, denosumab use in hypercalcemia urgency (not hypercalcemia of malignancy): - Currently, little reliable information is available regarding the use of denosumab for hypercalcemia urgency related to parathyroid hormone abnormality. This medication is relatively long acting, so clinical response could be delayed (up to a week or longer for time to response and complete response seen out to 3+ weeks). There is currently no criteria set or protocol for using denosumab in hypercalcemia urgency at Huntsville Hospital; use should be evaluated on a case by case basis. (Drug Info statement December 2022)
Reviewed: August 24, 2010 (Prolia) and March 22, 2011 (Xgeva), June 2025 (Ospomyy,Stoboclo,Conexxence, and Jubbonti)
REMS (Prolia): View FDA REMS Info